• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bicycle Therapeutics plc (Amendment)

    2/14/24 4:08:54 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCYC alert in real time by email
    SC 13G/A 1 tm244195-1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, DC 20549

     

    SCHEDULE 13G 

    (Amendment No. 4)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 19341

     

    Bicycle Therapeutics plc 

    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.01 

    (Title of Class of Securities)

     

    088786 10 8 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b) 

    x Rule 13d-1(c) 

    ¨ Rule 13d-1(d)

     

    ______________________

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Ridgeback Capital Investments L.P.           66-0677421
     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    -0-
    6. SHARED VOTING POWER
    844,235*
    7. SOLE DISPOSITIVE POWER
    -0-
    8. SHARED DISPOSITIVE POWER
    844,235*
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


    844,235*

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES** ¨
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    2.2%
    12. TYPE OF REPORTING PERSON**
    OO
      * Consists of 844,235 American Depositary Shares, representing 844,235 ordinary shares, nominal value £0.01.   
               

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Ridgeback Capital Investments LLC             72-1614961
     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    -0-
    6. SHARED VOTING POWER
    844,235*
    7. SOLE DISPOSITIVE POWER
    -0-
    8. SHARED DISPOSITIVE POWER
    844,235*
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    844,235*
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES** ¨
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    2.2%
    12. TYPE OF REPORTING PERSON**
    OO
      * Consists of 844,235 American Depositary Shares, representing 844,235 ordinary shares, nominal value £0.01.    
               

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 4 of 10

     

    1.

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Ridgeback Capital Management LLC          42-1684320

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
      NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    -0-
    6. SHARED VOTING POWER
    844,235*
    7. SOLE DISPOSITIVE POWER
    -0-
    8. SHARED DISPOSITIVE POWER
    844,235*
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    844,235*
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES** ¨
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    2.2%
    12. TYPE OF REPORTING PERSON**
    OO
      * Consists of 844,235 American Depositary Shares, representing 844,235 ordinary shares, nominal value £0.01.  
               

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 5 of 10

     

    Item 1(a). Name of Issuer.

     

    Bicycle Therapeutics plc (the “Company”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The Company’s principal executive offices are located Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, United Kingdom.

     

    Items 2(a). Name of Person Filing.

     

    This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the “Shares”):

     

    (i)            Ridgeback Capital Investments L.P., Delaware limited partnership (“RCILP”), with respect to Shares beneficially owned by it;

     

    (ii)           Ridgeback Capital Investments LLC, a Delaware limited liability company (“RCI”), with respect to Shares beneficially owned by it; and

     

    (iii)          Ridgeback Capital Management LLC, a Delaware limited liability company (“RCM”), with respect to Shares beneficially owned by it.

     

    The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    The address of the principal business office of each of the Reporting Persons is 30 Star Island Drive, Miami, FL, 33139.

     

    Item 2(c).Citizenship.

     

    RCILP is a Delaware limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

     

    Item 2(d).Title of Class of Securities.

     

    Ordinary shares, nominal value £0.01 per share. The Reporting Persons beneficially own American Depositary Shares (“ADS”). Each ADS represents one ordinary share.

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 6 of 10

     

    Item 2(e).CUSIP Number.

     

    088786 10 8

     

    Item 3.

     

    If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

     

    (a) ¨

    Broker or dealer registered under Section 15 of the Act,

     

    (b) ¨

    Bank as defined in Section 3(a)(6) of the Act,

     

    (c) ¨

    Insurance Company as defined in Section 3(a)(19) of the Act,

     

    (d) ¨

    Investment Company registered under Section 8 of the Investment Company Act of 1940,

     

    (e) ¨

    Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),

     

    (f) ¨

    Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),

     

    (g) ¨

    Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),

     

    (h) ¨

    Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,

     

    (i) ¨

    Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,

     

    (j) ¨

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),

     

    (k) ¨

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________. 

     

    Item 4.Ownership.

     

    The percentages used herein are calculated based upon 37,715,666 ordinary shares outstanding as of October 30, 2023 as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 2, 2023. As of the close of business on December 31, 2023, the Reporting Persons beneficially owned shares of the Company’s common stock in the amounts and percentages listed below:

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 7 of 10

     

    A. Ridgeback Capital Investments L.P.
    (a) Amount beneficially owned:  844,235
    (b) Percent of class: 2.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  844,235
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  844,235
         
    B. Ridgeback Capital Investments LLC
    (a) Amount beneficially owned:  844,235
    (b) Percent of class: 2.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  844,235
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  844,235
       
    C. Ridgeback Capital Management LLC
    (a) Amount beneficially owned:  844,235
    (b) Percent of class: 2.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  844,235
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  844,235

     

    RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 2.2% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 8 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.      ⌧

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATED: February 14, 2024

     

       

    Ridgeback Capital Investments L.P.

     

        By: Ridgeback Capital Investments LLC,
       

    Its General Partner

     

      By:  /s/ Nicole Venezia
        Name:  Nicole Venezia
        Title:  General Counsel

     

       

    Ridgeback Capital Investments LLC

     

      By:  /s/ Nicole Venezia
        Name:  Nicole Venezia
        Title:  General Counsel

     

       

    Ridgeback Capital Management LLC

     

      By: /s/ Nicole Venezia
        Name:  Nicole Venezia
        Title:  General Counsel

     

     

     

     

    CUSIP NO. 088786 10 8 13G Page 10 of 10

     

    EXHIBIT INDEX

     

    Exhibit Number Exhibit Description
    99.1 Joint Filing Agreement*

     

    _________________ 

    *Previously filed.

     

     

     

    Get the next $BCYC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCYC

    DatePrice TargetRatingAnalyst
    11/8/2024$25.00Equal-Weight
    Stephens
    9/6/2024$35.00Outperform
    RBC Capital Mkts
    8/7/2024$33.00 → $28.00Buy → Neutral
    B. Riley Securities
    9/11/2023Neutral → Buy
    B. Riley Securities
    8/31/2022Outperform
    Cowen
    7/28/2022$30.00Overweight
    Barclays
    7/6/2022$60.00Buy
    Canaccord Genuity
    4/13/2022$62.00 → $33.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $BCYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Bicycle Therapeutics with a new price target

      Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00

      11/8/24 7:35:57 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Bicycle Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00

      9/6/24 7:31:26 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously

      8/7/24 6:40:33 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $6.95 per share, Bicycle Therapeutics' closing trading price on June 30, 2025, and will vest over four years, with 25%

      7/2/25 4:05:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 57,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $8.22 per share, Bicycle Therapeutics' closing trading price on May 30, 2025, and will vest over four years, with 25% o

      6/3/25 4:05:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

      Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer Poster Session: Genitourinary Cancer—Kidney and Bladder Date and Time: Mon

      5/22/25 5:05:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    SEC Filings

    See more
    • SEC Form 144 filed by Bicycle Therapeutics plc

      144 - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      7/2/25 4:06:59 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

      6/17/25 5:08:03 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

      SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      5/15/25 4:34:33 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $21,230,385 worth of American Depositary Shares (1,485,397 units at $14.29) (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      12/17/24 6:03:39 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Lee Kevin sold $39,836 worth of Ordinary Shares (5,461 units at $7.29), decreasing direct ownership by 1% to 480,804 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      7/7/25 5:20:14 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Young Alethia sold $1,446 worth of Ordinary Shares (204 units at $7.09), decreasing direct ownership by 0.45% to 45,186 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      7/7/25 5:20:04 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF ACCOUNTING OFFICER Thompson Travis Alvin sold $2,205 worth of Ordinary Shares (306 units at $7.20), decreasing direct ownership by 0.96% to 31,521 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      7/7/25 5:20:06 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

      SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      12/17/24 6:46:27 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

      SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      11/14/24 5:46:12 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

      SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      11/14/24 4:32:50 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Financials

    Live finance-specific insights

    See more
    • Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

      Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and

      12/12/24 6:30:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

      Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the

      11/25/24 5:30:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

      First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap

      10/23/24 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

      Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

      2/25/25 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

      Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance

      12/10/24 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

      EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS

      10/19/23 4:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care